| 引用本文:杨丽1，张艳春2，刘晓冉3.益气散结方联合恩替卡韦治疗失代偿期乙型肝炎肝硬化患者的临床疗效分析[J].世界中医药,2017,(03):. |
|
| 益气散结方联合恩替卡韦治疗失代偿期乙型肝炎肝硬化患者的临床疗效分析 |
| Clinical Effects of Patients with Decompensatory Hepatitis B Cirrhosis Treated with Qi-Replenishing Mass-Dissipating Formula and Entecavir |
| 投稿时间：2016-06-17 |
| DOI：10.3969/j.issn.1673-7202.2017.03.016 |
| 中文关键词: 益气散结方 恩替卡韦 失代偿期 乙型肝炎肝硬化 腹水 临床疗效 |
| English Keywords:Qi-Replenishing Mass-Dissipating Formula Entecavir Decompensation Hepatitis B cirrhosis Clinical effects |
| 基金项目:石家庄市科技局研究与发展指导计划项目(编号:071461333) |
|
| 摘要点击次数: 830 |
| 全文下载次数: 984 |
| 中文摘要: |
| 目的:探讨益气散结方联合恩替卡韦治疗乙型肝炎肝硬化失代偿期的临床疗效分析。方法:选取2014年6月至2015年6月石家庄市第五医院收治的代偿期乙型肝炎肝硬化患者64例,随机分为对照组和观察组,各32例,对照组给予给予保肝、对症、支持疗法等常规治疗,而观察组则在对照组的基础上给予恩替卡韦联合益气散结方治疗。比较2组患者治疗前后血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBil)以及白蛋白(ALB)的的水平的变化。检测患者治疗前后的门静脉内径(PVD)、脾静脉血管内径(SVD)、门静脉血流量(PVQ)以及脾静脉血流量(SVQ),并于治疗前后对患者进行Child-Pugh评分,比较2组患者治疗后的腹水消失率。结果:观察组患者治疗后的ALT、AST和TBil水平显著低于对照组,2组间差异有统计学意义(P<0.05);观察组患者治疗后的ALB水平显著高于对照组,2组间差异有统计学意义(P<0.05);观察组患者治疗后的PVD、SVD、PVQ和SVQ显著低于对照组,2组间差异有统计学意义(P<0.05);观察组患者治疗后的Child-Pugh评分显著低于对照组,2组间差异有统计学意义(P<0.05);观察组患者治疗后HBV-DNA阴转率和腹水消失率均显著高于对照组,2组间差异有统计学意义(P<0.05)。结论:益气散结方联合恩替卡韦治疗失代偿期乙型肝炎肝硬化,能有效抑制乙型肝炎病毒的复制,改善患者的临床症状和肝功能,值得应用于临床。 |
| English Summary: |
| To discuss clinical effects of Qi-Replenishing Mass-Dissipating Formula and entecavir in the treatment of decompensatory hepatitis B cirrhosis.Methods:A total of 64 patients with decompensatory hepatitis B cirrhosis were selected and divided into treatment group and control group (n=32).The control group were treated with liver protective,symptomatic and supporting treatments while the other 32 patients in treatment group treated with Qi-Replenishing Mass-Dissipating Formula and Entecavir on the control group’s treatment.And the levels of ALT,AST,TBil and ALB in two group before and after treatments,the PVD,SVD,PVQ and SVQ in two group before and after treatments were evaluated.Child-Pugh before and after treatments were graded,and disappearance rate of peritoneal dropsy were compared.Results:The levels of ALT,AST and TBil in treatment group were lower than the control group after treatments,differences were statistically significant (P<0.05）;The level of ALB after treatments in control group was higher than that in control group,difference was statistically significant (P<0.05）;The PVD,SVD,PVQ and SVQ after treatments in treatment group were lower than the control group,differences were statistically significant (P<0.05）;The scores of Child-Pugh after treatments in treatment group were lower than control group,differences were statistically significant (P<0.05）; The negative conversion rate of HBV-DNA and disappearance rate of peritoneal dropsy after treatments in treatment group were higher than control group,differences were statistically significant (P<0.05）.Conclusion:Qi-Replenishing Mass-Dissipating Formula and entecavir treatment can help prevent the virus replication,and improve the clinical symptoms and liver function when treating decompensatory hepatitis B cirrhosis,which is worth of clinical usage. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
